Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Clinical Psychopharmacology and Neuroscience ; : 139-142, 2019.
Article Dans Anglais | WPRIM | ID: wpr-739461

Résumé

Treatment of burning mouth syndrome (BMS) is challenging because there is no consensus regarding pharmalogical or nonpharmalogical therapies. The use of anticonvulsants is controversial. We present nine patients BMS who respond to pregabalin. They were diagnosed secondary BMS except two. Etiologic regulations were made firstly in patients with secondary BMS but symptoms did not decrease. We preferred pregabalin in all patients and got good results. Furthermore the addition of pregabalin to the treatment of two patients who did not respond adequately to duloxetine provided good results. We are only aware that pregabalin may reduce symptoms as a result of case reports. We believe that the diagnosis of pathologic etiology with appropriate diagnostic tests will result in better outcomes in treatment.


Sujets)
Humains , Anticonvulsivants , Stomatodynie , Brûlures , Consensus , Diagnostic , Tests diagnostiques courants , Chlorhydrate de duloxétine , Prégabaline , Contrôle social formel
SÉLECTION CITATIONS
Détails de la recherche